human
blood
collect
accumul
vast
trove
biochem
molecul
go
differ
organ
tissu
ultim
reflect
physiolog
patholog
statu
bodi
therebi
provid
valuabl
inform
earli
diagnosi
prognosi
well
monitor
therapeut
effici
cumul
evid
suggest
lowmolecularweight
lmw
region
human
serum
proteom
includ
small
intact
protein
truncat
fragment
larger
protein
along
small
compon
implic
variou
human
diseas
cancer
diabet
cardiovascular
infecti
diseas
repres
treasur
trove
diagnost
molecul
sever
fact
might
support
view
begin
lmw
protein
usual
made
physiolog
import
protein
cytokin
growth
factor
peptid
hormon
well
proteinspeptid
origin
normal
cell
tissu
leakag
result
cell
death
damag
believ
import
reflect
valuabl
diseaserel
inform
highabund
protein
diagnost
point
view
instanc
lmw
protein
famili
human
serum
amyloid
saa
hot
spot
field
biomark
research
associ
variou
type
cancer
ovarian
cancer
lung
cancer
pancreat
cancer
well
diseas
like
coronari
arteri
diseas
obes
sever
acut
respiratori
syndrom
moreov
increas
evid
show
tumor
cell
excret
biomolecul
kda
bloodstream
specif
tumor
type
rate
proport
tumor
ages
second
lmw
protein
readili
enter
blood
contrast
larger
protein
enter
bloodstream
intact
activ
secret
vascular
wall
becom
permeabl
owe
diseas
lmw
protein
small
enough
enter
blood
passiv
produc
diagnost
trace
fact
mani
lmw
protein
peptid
potenti
contain
diseasespecif
inform
found
fragment
deriv
larger
parent
molecul
normal
larg
passiv
diffus
endothelium
circul
third
proteinasemedi
ex
vivo
enzymat
cleavag
part
coagul
complement
activ
pathway
also
lead
produc
lmw
protein
biomark
realli
true
circul
blood
alreadi
contain
abund
protein
fragment
appar
deriv
cell
tissu
produc
vivo
instanc
villanueva
cowork
show
diagnost
protein
fragment
gener
ex
vivo
circul
enzym
deriv
diseas
tissu
microenviron
act
exogen
deriv
peptid
produc
serum
collect
methodolog
howev
identif
lmw
protein
human
serumplasma
analyt
challeng
due
sever
aspect
first
dynam
complex
serumplasma
span
order
magnitud
term
concentr
greatli
hinder
character
lmw
protein
known
mani
highabund
protein
exist
concentr
billionfold
higher
lowabund
lmw
protein
therebi
mask
potenti
lmw
protein
biomark
hinder
detect
instanc
human
plasma
proteom
abund
protein
includ
albumin
immunoglobulin
fibrinogen
alpha
alpha
respons
bulk
mass
total
protein
content
human
plasma
protein
like
albumin
even
reach
concentr
mgml
serum
second
compound
rel
low
concentr
lmw
biomark
present
circul
level
lmw
protein
serum
estim
low
picomol
even
femtomol
accur
consist
comprehens
measur
difficult
moreov
cumul
evid
show
mani
lmw
protein
serum
consist
truncat
solubl
form
result
vivo
ex
vivo
cleavag
lower
concentr
protein
decreas
detect
inde
degrad
target
biomark
occur
transport
storag
blood
lead
seriou
falseposit
falseneg
result
third
filtrat
molecul
glomerular
capillari
wall
glomerular
filtrat
highli
depend
molecul
size
refer
filtrations
threshold
mean
size
protein
gener
determin
fast
would
clear
blood
kidney
filtrat
uptak
liver
instanc
insulin
achiev
renal
filtrat
blood
halflif
min
therefor
lmw
molecul
gener
vivo
would
clear
rather
quickli
therebi
reduc
concentr
molecul
potenti
undetect
level
last
least
effect
way
small
protein
avoid
rapidli
clear
mention
earlier
stay
circul
hitch
ride
carrier
protein
realli
true
mani
studi
show
lmw
biomark
associ
noncoval
highmolecularweight
hmw
protein
therefor
remov
hmw
protein
sampl
may
dilut
sampl
lmw
biomark
mention
earlier
character
lowabund
lmw
protein
difficult
task
order
simplifi
biomark
discoveri
lmw
region
wide
rang
technolog
util
mainli
fall
two
strategi
fig
prefraction
reduc
dynam
complex
enrich
lmw
protein
enhanc
detect
sensit
modifi
sampl
protein
distribut
prefraction
strategi
allow
protein
initi
present
low
concentr
access
analysi
henc
mani
differ
fractionationsepar
techniqu
consid
protein
biochem
biophys
properti
molecular
weight
isoelectr
point
hydrophob
well
effici
reproduc
develop
appli
multidimension
fashion
enhanc
detect
lowabund
protein
human
serum
plasma
due
great
mask
effect
creat
highabund
protein
lmw
protein
detect
deplet
highabund
protein
becom
one
commonli
appli
strategi
reduc
dynam
complex
serumplasma
inde
tu
cowork
reveal
remov
top
top
highabund
protein
shown
result
increas
number
identifi
protein
far
sever
differ
approach
commonli
use
remov
highabund
protein
human
serumplasma
includ
organ
solvent
precipit
centrifug
ultrafiltr
affinitybas
techniqu
simplest
approach
deplet
highabund
protein
serum
would
precipit
protein
organ
solvent
methanol
acetonitril
ammonium
sulfat
inorgan
salt
hmw
protein
mw
kda
would
precipit
lowermolecularweight
one
would
remain
supernat
far
acetonitril
precipit
shown
effect
precipit
larg
abund
protein
serum
believ
superior
method
remov
serum
albumin
immunoglobulin
serum
may
due
fact
acn
denatur
larg
protein
allow
remov
caus
small
lowabund
protein
peptid
normal
bound
carrier
protein
dissoci
thu
make
avail
detect
inde
experi
suggest
mass
spectrometri
ms
analysi
serum
lmw
protein
greatli
improv
enhanc
signal
intens
higher
resolut
fig
facilit
trace
target
protein
howev
caution
requir
risk
coprecipit
lowabund
protein
would
great
centrifug
ultrafiltr
util
centrifug
forc
semiperm
membran
retain
hmw
protein
lmw
protein
pass
membran
filtrat
nomin
molecular
weight
cutoff
anoth
common
strategi
deplet
highabund
protein
human
serumplasma
howev
critic
disrupt
peptideproteinprotein
interact
prior
centrifug
ultrafiltr
releas
lmw
compon
bound
larger
speci
mani
physiolog
import
lowabund
protein
often
found
bound
carrier
protein
plasma
moreov
import
recogn
retent
protein
centrifug
ultrafiltr
membran
determin
varieti
factor
includ
molecular
weight
molecular
shape
electr
charg
sampl
concentr
buffer
composit
oper
condit
therefor
multipl
studi
show
hmw
protein
still
appear
filtrat
use
differ
commerci
avail
filter
membran
one
reason
suppos
shape
hmw
protein
chang
denatur
therebi
lead
size
chang
make
pass
membran
therefor
multidimension
separ
combin
centrifug
ultrafiltr
reversedphas
solidphas
extract
recommend
improv
enrich
lmw
protein
peptid
organ
solvent
precipit
centrifug
ultrafiltr
approach
mention
earlier
quit
nonselect
gener
remov
hmw
protein
remov
highabund
protein
serum
specif
mani
techniqu
base
affin
matric
antibodi
antibodymimick
peptid
kind
natur
compound
often
employ
instanc
popular
method
remov
hsa
use
cibacron
bluebas
affin
chromatographi
deplet
immunoglobulin
second
abund
serumplasma
protein
use
immobil
protein
g
media
specif
bind
fc
region
igg
techniqu
choic
howev
deplet
hsa
dyebas
resin
entir
straightforward
due
enorm
load
hsa
speci
serum
plasma
nonspecif
bind
serum
protein
well
moreov
cibacron
blue
dye
show
affin
albumin
also
nad
fad
atpbind
site
protein
often
result
unwant
remov
protein
interest
addit
protein
antibodi
captur
also
show
wide
vari
degre
affin
antibodi
isotyp
subtyp
result
incomplet
remov
subtyp
igg
therefor
use
specif
ligand
captur
hsa
igg
antibodi
employ
steel
cowork
demonstr
develop
immuneaffin
resin
use
monoclon
antibodi
hsa
effect
remov
fulllength
hsa
mani
hsa
fragment
present
serum
show
markedli
better
perform
dyebas
resin
term
effici
specif
albumin
remov
furthermor
protein
g
affin
resin
use
togeth
immunoaffin
resin
igg
hsa
simultan
remov
sampl
howev
still
leav
behind
mani
highabund
protein
though
singleantibodi
column
specif
igg
hsa
captur
good
percentag
target
protein
thu
select
simultan
remov
singl
highabund
protein
becam
desir
last
decad
gradual
develop
sever
multipl
affin
remov
column
simultan
deplet
even
highabund
protein
multipl
affin
remov
system
mar
agil
technolog
santa
clara
california
combin
specif
antibodyantigen
recognit
effici
standard
liquid
chromatographi
one
first
mar
market
affin
column
remov
hsa
igg
transferrin
alpha
haptoglobin
immunoglobulin
use
six
affinitypurifi
polyclon
antibodi
bond
polymer
microbead
via
fc
region
number
commerci
product
base
upon
specif
antibodi
highabund
protein
use
ionexchang
mechan
also
design
remov
highabund
protein
serum
plasma
product
claim
rang
deplet
protein
way
protein
seppro
proteoprep
sigma
aldrich
well
proteospin
norgen
biotek
corp
howev
caution
requir
recent
evid
shown
increas
number
deplet
protein
littl
benefici
effect
could
fact
even
increas
remov
peptid
protein
interest
associ
abund
protein
addit
next
layer
abund
protein
moder
abund
protein
separ
highli
abund
protein
becom
obstacl
access
lowabund
protein
tackl
challeng
fang
cowork
develop
igymicrobead
system
immun
chicken
flowthrough
fraction
column
construct
column
affinitypurifi
igi
antibodi
flowthrough
protein
column
enabl
specif
captur
moder
abund
protein
therebi
enabl
deeper
effect
access
popul
lap
even
though
sever
method
avail
mention
earlier
fraction
remov
protein
sampl
decreas
dynam
rang
lmw
protein
human
serumplasma
still
present
complex
mixtur
remain
big
challeng
identifi
target
protein
serumplasma
without
enrich
isol
subsequ
effici
enrich
isol
procedur
need
reduct
sampl
complex
therebi
purif
identif
target
protein
contrast
deplet
techniqu
specif
enrich
process
allow
fast
high
specif
detect
picomolar
even
femtomolar
quantiti
target
protein
one
enrich
process
magnet
bead
coat
ligand
interest
enabl
identifi
lowabund
lmw
protein
faster
effici
lower
cost
method
may
primarili
due
fact
magnet
particl
compris
conveni
solid
support
varieti
assay
procedur
base
affin
purif
instanc
high
densiti
bead
allow
rapid
captur
magnet
devic
visibl
bead
ensur
reliabl
collect
target
protein
bound
immunoprecipitationpulldown
applic
allow
concentr
lowabund
target
protein
sampl
millilit
microlit
scale
anderson
cowork
report
siscapa
stabl
isotop
standard
captur
antipeptid
antibodi
method
specif
antibodybas
captur
individu
tryptic
peptid
digest
whole
human
plasma
base
simplifi
magnet
bead
protocol
protocol
select
tryptic
peptid
lipopolysaccharidebind
protein
enrich
rel
highabund
serum
albumin
peptid
respect
measur
multipl
reaction
monitor
mrm
contrast
magnet
bead
excel
properti
smallscal
experi
experiment
featur
antibodi
microarray
advantag
perform
simultan
enrich
sever
hundr
protein
parallel
desrosi
cowork
demonstr
proteom
analysi
human
plasma
protein
use
antibodi
array
coat
antibodi
direct
signal
protein
remov
deplet
highabund
protein
result
show
antibodi
microarray
allow
identif
lowerabund
plasma
protein
use
antibodi
direct
signal
protein
author
suggest
strategi
valuabl
approach
detect
potenti
plasma
biomark
altern
innov
strategi
base
combinatori
solidphas
librari
also
call
proteomin
proteomin
technolog
biorad
combinatori
solidphas
librari
contain
larg
highli
divers
librari
hexapeptid
bound
chromatograph
support
allow
uniqu
hexapeptid
bind
uniqu
protein
sequenc
sampl
ad
limit
bind
capac
bead
enabl
highabund
protein
rapidli
satur
ligand
excess
protein
wash
howev
caution
requir
one
potenti
pitfal
remain
regard
elut
target
molecul
specif
enrich
antibodi
high
select
case
lowabund
protein
small
amount
protein
elut
antibodi
easili
lost
follow
procedur
nanotechnolog
advanc
microfabr
offer
great
opportun
provid
nanoharvest
agent
design
specif
captur
amplifi
class
lmw
protein
fact
past
year
varieti
type
nanoparticl
appli
captur
separ
protein
complex
mixtur
among
nanomateri
golden
nanoparticl
gnp
found
readili
avail
rel
stabl
low
toxic
excel
compat
biomolecul
selfassembl
monolay
technolog
increas
gnp
solubl
improv
interfaci
interact
coat
select
function
motif
gnp
function
harvest
lmw
protein
recent
khouri
cowork
demonstr
poli
acryl
acid
coat
gold
np
creat
layerbylay
method
use
select
harvest
posit
charg
lmw
biomark
kda
sdfr
fitclabel
peptid
one
step
addit
special
affin
baitcontain
hydrogel
particl
simultan
conduct
molecular
siev
chromatographi
affin
chromatographi
one
step
shown
great
promis
lmw
protein
harvest
cumul
evid
show
hydrogel
particl
conduct
enrich
encapsul
select
class
protein
peptid
complex
mixtur
biomolecul
nativ
human
serum
urin
purifi
endogen
highabund
protein
albumin
protect
degrad
subsequ
sampl
handl
carbon
nanotub
anoth
type
import
nanomateri
use
enrich
lowabund
lmw
protein
due
extraordinari
electron
mechan
properti
cnt
offer
number
advantag
enrich
protein
may
result
effici
enrich
nanoparticl
cnt
larg
inner
volum
allow
molecul
encapsul
volum
easili
access
end
cap
easili
remov
addit
distinct
inner
outer
surfac
function
biocompat
capabl
recogn
protein
broadli
cnt
may
class
either
singlewal
nanotub
swnt
multiwal
nanotub
mwnt
mwnt
compos
sever
coaxial
layer
swnt
allow
interact
strongli
organ
molecul
therebi
might
offer
interest
opportun
develop
new
uniqu
adsorb
materi
captur
lmw
protein
li
cowork
describ
novel
peptidom
analysi
approach
use
multiwal
carbon
nanotub
altern
adsorb
captur
endogen
peptid
human
plasma
coupl
liquid
chromatographymass
spectrometri
method
allow
detect
peptid
featur
mz
rang
plasma
due
welldefin
pore
network
surfac
reactiv
use
mesopor
silica
surfac
sizeexclus
method
harvest
peptid
small
protein
also
wide
report
addit
chemic
structur
modif
porou
silicon
enabl
optim
ioniz
porou
silicon
surfac
allow
sensit
compat
siliconbas
microfluid
microchip
technolog
base
nanopor
surfac
use
captur
lmw
peptid
human
plasma
instanc
fan
cowork
describ
peptid
extract
approach
base
nanopor
silica
thin
film
success
detect
low
concentr
hepcidin
human
bodi
fluid
collect
healthi
volunt
inflamm
patient
recent
tang
cowork
report
approach
adsorpt
enrich
lowabund
protein
mammalian
cell
extract
use
nanostructur
surfaceimprint
polym
suffici
thin
shell
high
surfacetovolum
ratio
virtu
high
sensit
high
resolut
high
accuraci
high
throughput
ms
becom
primari
tool
identif
quantif
protein
serumplasma
character
lmw
protein
plasma
two
fundament
differ
msbase
strategi
discoverybas
identif
target
quantif
discoverybas
strategi
goal
usual
discov
protein
associ
ongo
physiolog
patholog
event
therebi
elucid
lmw
protein
ident
clinic
valid
msbase
strategi
frequent
use
identif
protein
alway
involv
combin
gelor
lcbase
separ
techniqu
ms
sdspage
coupl
maldi
esim
ms
lcmaldiesim
ms
howev
prior
effort
search
serum
plasma
protein
biomark
util
gelbas
separ
technolog
show
gel
readili
separ
distinguish
molecul
less
kda
size
contrast
highperform
liquid
chromatographi
hplc
separ
coupl
ms
highli
autom
capac
separ
lowabund
protein
subsequ
detach
thu
wide
use
separ
protein
serumplasma
highabund
protein
deplet
typic
esimsmsbas
experi
especi
lcmsm
approach
protein
digest
peptid
peptid
ion
select
mass
spectromet
fragment
gener
tandem
mass
spectra
sequenc
involv
automat
sophist
bioinformat
tool
laser
desorptionion
techniqu
seldi
maldi
base
experi
mani
report
biomark
limit
gener
descript
protein
peak
due
inher
low
resolut
mass
accuraci
selditofm
limit
capabl
tandem
msm
protein
analysi
malditofm
therefor
addit
effici
isol
procedur
need
elucid
lmw
protein
ident
group
develop
approach
combin
pipett
tip
desalt
acetonitril
acn
precipit
reversephas
hplc
purif
malditofm
analysi
fig
believ
suitabl
profil
purif
identif
lowabund
lmw
target
protein
human
serum
use
workflow
purifi
identifi
saa
isoform
without
truncat
sera
advancedstag
cancer
patient
target
quantif
lmw
protein
sever
strategi
appli
mainli
fall
two
categori
select
reaction
monitor
srm
also
term
mrm
parallel
reaction
monitor
prm
due
high
specif
sensit
mrm
present
wide
use
msbase
target
proteom
approach
mrm
typic
carri
tripl
quadrupol
qqq
mass
spectromet
first
mass
analyz
set
transmit
target
ion
select
peptid
collis
energi
optim
produc
diagnost
charg
fragment
ion
second
mass
analyz
third
mass
analyz
set
transmit
one
three
select
diagnost
fragment
monitor
fig
advantag
mrm
compar
quantit
analyt
method
western
blot
elisa
immunohistochemistri
includ
multiplex
detect
abil
use
spikedin
stabl
isotopelabel
standard
foster
absolut
precis
rel
quantif
endogen
analyt
mrm
assay
approach
appli
measur
variou
lowabund
specif
peptid
tryptic
digest
plasma
creactiv
protein
prostatespecif
antigen
prm
first
publish
target
proteom
strategi
product
ion
target
peptid
simultan
monitor
highresolut
high
mass
accuraci
principl
prm
compar
srmmrm
permit
parallel
detect
target
product
ion
one
highresolut
mass
analysi
third
quadrupol
qqq
mass
spectromet
substitut
highresolut
accuratemass
analyz
prm
case
fig
sever
advantag
prm
compar
mrm
begin
prm
perform
full
scan
fragment
ion
instead
record
transit
mrm
enabl
highqual
quantit
measur
moreov
background
interfer
could
greatli
elimin
high
resolut
accuraci
fig
workflow
target
protein
purif
identif
human
sera
thu
improv
detect
limit
sensit
complex
background
effect
addit
requir
minim
upfront
effort
select
target
transit
optim
fragment
energi
facilit
assay
develop
thu
prm
believ
suitabl
quantif
multipl
protein
low
abund
complex
sampl
instanc
kim
cowork
develop
prm
assay
select
measur
isotyp
saa
success
measur
five
allel
variant
plasma
sampl
lung
cancer
patient
ronsein
et
al
develop
prm
method
quantif
highdens
lipoprotein
proteom
plasma
sampl
use
nlabel
apolipoprotein
intern
standard
despit
variou
advanc
character
lowabund
lmw
protein
human
serumplasma
still
mani
challeng
remain
instanc
even
though
signific
recent
advanc
current
proteom
technolog
still
fall
short
abl
reliabl
detect
blood
plasma
low
ngml
subngml
protein
concentr
level
detect
often
requir
discov
diseasespecif
biomark
moreov
deplet
highabund
protein
could
potenti
allevi
mask
effect
howev
remov
reduct
highabund
protein
without
affect
minor
protein
repres
challeng
furthermor
sampl
prepar
introduc
preanalyt
variat
pose
major
challeng
analyz
serum
proteom
therefor
possibl
develop
new
technolog
strategi
allow
select
identif
quantif
lmw
protein
serumplasma
may
acceler
discoveri
rate
potenti
biomark
drug
target
